MedTrace Logo

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

NCT01167088 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2011-06-01

No results posted yet for this study

Summary

The purpose of this study is to investigate whether a new medicine, called mitoquinone, will reduce raised liver enzymes due to NAFLD and to see if it is safe.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

DRUG

Mitoquinone mesylate

2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Antipodean Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Chris Day, MD, PhD · Newcastle University Medical School, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-06-30
Completion
2011-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01167088 on ClinicalTrials.gov